DeNovX scientists have been busy this year presenting their research showing improvements in crystallization outcomes for proteins and small molecule active pharmaceutical ingredients (APIs). Presentations at the 2018 and 2019 American Crystallographic Association meetings highlighted protein crystallization trials using the company's surface science approach to improving crystallization along with a unique report on continuous flow manufacturing using an antisolvent crystallization system. DeNovX Co-founder Andrew Bond also delivered presentations at the Spring and Fall American Chemical Society meetings highlighting batch crystallization results for proteins and small molecule APIs that consistently showed improvements in crystallization hit rates and onset times. As part [...]

DeNovX completed four data collection campaigns at the Advanced Photon Source at Argonne National Laboratory in 2018. A three person team of DeNovX scientists set an internal productivity record by mounting on site and delivering 94 protein crystals to the X-ray beam yielding a total of 72 full data sets for crystal quality studies - all in just 17.9 hours!

This Japanese patent is the follow on to issued US patent number 9,193,664 that covers new and more efficient methods of improving crystallization outcomes for compounds used in the food, pharmaceutical, medical nutrition, nutraceutical, cosmetic, agricultural, fine chemicals, and bioengineering fields. Early adopters in pharmaceutical R&D and specialty Contract Research Organizations (CROs) stand to benefit substantially as the crystallization of small molecule Active Pharmaceutical Ingredients (APIs) remains a challenging early step in drug development.

DeNovX is pleased to announce the establishment of a collaboration with scientists in the Center for Structural Genomics of Infectious Diseases (CSGID) at Argonne National Laboratory. This effort is funded through a Phase II SBIR award to DeNovX, and it will provide an opportunity to investigate the crystallization of high impact, infectious disease-related proteins produced in the CSGID pipeline. Once crystalline, these proteins will be characterized at the Midwest Center for Structural Genomics' beamline at the Advanced Photon source.

The initial publication describing DeNovX's patented approach to improving crystallization outcomes using its surface science approach was published in the American Chemical Society's premier peer reviewed journal Crystal Growth & Design on July 21, 2017. The document is now available by open access: Crystal Nucleation Using Surface-Energy-Modified Glass Substrates.

The National Institutes of Health have awarded DeNovX a Phase I SBIR grant of $311,500 to apply its innovative, patented crystallization technologies to the discovery and characterization of co-crystalline materials. Co-crystals are a combination of two or more different compounds (i.e., the "co-") that crystallize individually into a single crystalline material (i.e., the "crystal"). This definition is evolving and remains a bit cumbersome, but the applications of co-crystalline materials are exciting and broad, with several co-crystalline pharmaceuticals already approved for use. The promise of co-crystals lay in the enormity of the molecular combinations that can be engineered to give crystalline materials with [...]

On March 24, 2016 the NIH awarded DeNovX its second Phase I grant of $225,000 to advance the company's patented flow crystallization technology, which is under exclusive license from Illinois Institute of Technology.  The work targets the development of more cost effective and efficient methods of manufacturing crystalline pharmaceuticals that may help to overcome shortages of therapeutic drugs.  Hundreds of times each year, life-saving pharmaceuticals encounter a lack of availability, or drug shortage, which is most often attributed to quality control issues, manufacturing problems, and sometimes business and profitability decisions.  Such drug shortages negatively affect patients by causing treatment delays, medication [...]